Navigation Links
PD-Rx Completes Call for Preferred A Stock
Date:8/8/2008

OKLAHOMA CITY, Aug. 8 /PRNewswire-FirstCall/ -- PD-Rx Pharmaceuticals, Inc., a publicly held corporation, (Pink Sheets: PDRX) today announced that it has completed a repurchase of all of its outstanding Preferred "A" stock.

The outstanding Preferred Shares of Class "A" 13.25% Cumulative Convertible Stock representing One Hundred and Sixty Five Thousand (165,000) shares has been repurchased by PD-Rx Pharmaceuticals, Inc. The stock call represents PD-Rx's position to improve the company's financial status, while creating an advantageous move for its common shareholders.

All outstanding share of the Preferred Class "A" Stock has been redeemed and will be delisted.

ABOUT THE COMPANY:

PD-Rx offers pharmaceutical and management strategies to the healthcare industry. Our management strategies focus on new products, solid business partners, and the specialized segment of the pharmaceutical industry. As a licensed FDA manufacturer and packager, PD-Rx offers a full spectrum of medications and specialized services. Our goal is to develop a matrix of cost containment tools and products that we can merge into any healthcare network to enhance patient care and improve managed care organizations bottom line. We provide proprietary products and prepackaged medications that are viewed by patient, insurance payers and healthcare providers as a progressive and responsive practice.

This press release contains "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks and uncertainties or other factors, which may cause actual results, performance or achievements expressed or implied by such forward-looking statements to vary from those forecast or implied in this release. Factors that might cause such a difference include, without limitation, decline in demand for the company's products or services, and the effect of general economic con
'/>"/>

SOURCE PD-Rx Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Eligard(R) six-month formulation successfully completes European approval procedure
2. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
3. EaglePicher Corporation Completes Transaction to Sell EaglePicher Boron, LLC to Ceradyne, Inc. for $69 Million
4. Symmetry Medical Completes Acquisition Of Specialty Surgical Instruments
5. GSI Securitization Completes Merger and Domicile Transfer
6. Medical Services International Inc. Completes Testing for European Union (EU) Application
7. Inverness Completes Acquisition of Cholestech
8. Billians HealthDATA Completes Comprehensive Long Term Care Database Update
9. Synova Completes Sale of $3.3 Million in Senior Convertible Notes and Warrants
10. Explorer completes the map ... for the bodys blueprint
11. Labopharm completes enrolment for Phase III clinical study for its once-daily trazodone antidepressant drug
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... Sunnyvale, CA (PRWEB) November 28, 2014 ... on December 2, 2014. This national movement was ... their communities by giving to local charities and causes. ... Thanksgiving Holiday, coincides with the kickoff of the holiday ... Friday is to shopping and Cyber Monday is to ...
(Date:11/28/2014)... 2014 Now that the holiday season ... of the nation's leading cash-for-junk-cars companies, is improving their ... be more competitive and help bring a little bit ... time of year. , Along with purchasing expensive gifts ... US also deal with large travel expenses during the ...
(Date:11/28/2014)... 2014 Novatus, a leading provider ... v5.1 which provides customers with greater reporting capabilities, ... , “As we continue to evolve and grow ... functionality and improved performance in response to requests ... Novatus. “With the enhancements that we have made ...
(Date:11/28/2014)... Dr. Andrew Campbell, one of the ... expansion of Quintessa Aesthetic Center into a third location ... W307 N1497 Golf Road in Suite 200 and will ... the new Delafield location will offer a variety of ... Botox, filler injectables , micro laser peels, chemical ...
(Date:11/28/2014)... Dr. Paul Vitenas, one of the most awarded ... Holiday Event for those in the area that would like to ... & Glow will take place on December 11, 2014, from 6:00 ... heart of Houston at 4208 Richmond Ave. , “We want ... will come and celebrate the season with us on December 11, ...
Breaking Medicine News(10 mins):Health News:Pathways Home Health & Hospice Joins #GivingTuesday; Annual Holiday Encourages Local Charitable Giving 2Health News:Pathways Home Health & Hospice Joins #GivingTuesday; Annual Holiday Encourages Local Charitable Giving 3Health News:Rusty's Auto Salvage Increasing Their Cash Offers to Help Drivers Save Throughout the Busy Holiday Season 2Health News:Novatus Releases v5.1 with New Advanced Reporting Capabilities 2Health News:Dr. Andrew Campbell to Expand Quintessa Aesthetic Center into Delafield 2Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 2Health News:Cosmetic Surgeon Dr. Paul Vitenas to Host Glitter & Glow Holiday Event 3
... 18, 2011 HIV-positive head and neck cancer patients ... toxicity rates as non-HIV-positive patients, despite prior reports to ... issue of the International Journal of Radiation OncologyBiologyPhysics ... Radiation Oncology (ASTRO). , Patients with HIV have a ...
... A new program designed to create comprehensive, integrated, whole-person ... a $3.9 million grant from the Colorado Health Foundation. ... in the Department of Family Medicine at the University of ... and national leaders from the mental health, substance use, and ...
... (HealthDay News) -- Seeing a character in a movie light ... motions, new research shows. In the study, functional MRI ... 17 nonsmokers as they watched movie scenes that featured smoking. ... activity in areas involved in movement of the hand they ...
... more likely to have seriously considered suicide than their peers ... Toronto , In a paper published online this week in ... differences among a sample of 6,647 adults, of whom 695 ... study found that men from divorced families had more than ...
... By Jenifer Goodwin HealthDay Reporter , TUESDAY, ... from patients suggest that a controversial treatment for multiple ... many physicians remain highly skeptical of the claims. ... Zamboni, a vascular surgeon from Italy, published an intriguing ...
... of Technology indicates that the incidence of maltreatment, including ... 25 percent higher among deaf and hard-of-hearing children than ... correlation between childhood maltreatment and higher rates of negative ... study, which was presented at the 2010 annual meeting ...
Cached Medicine News:Health News:HIV-positive head and neck cancer patients benefit from radiation therapy 2Health News:New program targeting whole-person health care gets major grant 2Health News:Smoking Scenes in Movies Light Up Smokers' Brains 2Health News:Parental divorce linked to suicidal thoughts 2Health News:Vein-Opening Treatment for MS Stirs Controversy 2Health News:Vein-Opening Treatment for MS Stirs Controversy 3Health News:Vein-Opening Treatment for MS Stirs Controversy 4Health News:Study: Abuse rates higher among deaf and hard-of-hearing children compared with hearing youths 2
(Date:11/27/2014)... 27, 2014 Hovione announced today ... Application with the U.S. Food and Drug Administration (FDA). ... developing improved drug delivery options for established drugs. ... novel formulation using a new patented crystalline base form ... widely prescribed oral antibiotics for acne. Currently, there are ...
(Date:11/26/2014)... Mass. , Nov. 26, 2014   ... AEX: PHIA) today announced expanded availability of its ... DuraDiagnost, DigitalDiagnost, MobileDiagnost wDR, MobileDiagnost Opta[i] , ProGrade ... these solutions now available in the U.S., and ... markets, the portfolio offers Philips, customers innovative solutions ...
(Date:11/26/2014)...  Cohen, Placitella & Roth, PC is investigating ... Nymox Pharmaceutical Corporation ("Nymox" or "Company") (NASDAQ: ... 31, 2011 through November 2, 2014 ("Class Period").  ... its officers and directors publically disseminated materially false ... and 20(a) of the Securities Exchange Act of ...
Breaking Medicine Technology:Hovione Files its First Investigational New Drug Application With the FDA 2Philips expands global reach of diagnostic X-Ray solutions 2Philips expands global reach of diagnostic X-Ray solutions 3Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 2Cohen, Placitella & Roth, PC Investigating Nymox Pharmaceutical Corporation for Failing to Disclose Material Information 3
... The LH 755 simplifies ... by integrating expert automation and ... It delivers reliable, accurate results ... the best slide quality with ...
For the quantitative determination of Creatine Kinase in serum....
For the quantitative determination of creatine kinase in serum. Kinetic Reaction measured at 340 nm. Linearity: 1500 IU/L at 37C....
For the quantitative determination of total glucose in serum....
Medicine Products: